281 related articles for article (PubMed ID: 12649297)
1. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
3. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Adams JU; Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
[TBL] [Abstract][Full Text] [Related]
4. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
5. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer SD; Burke TF; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
7. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
8. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
9. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
Morgan D; Picker MJ
Psychopharmacology (Berl); 1998 Nov; 140(1):20-8. PubMed ID: 9862398
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
Picker MJ; Cook CD
Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
[TBL] [Abstract][Full Text] [Related]
11. Delta opioid-like discriminative stimulus effects of mu opioids in pigeons discriminating the delta opioid BW373U86 from saline.
Picker MJ; Cook CD
Behav Pharmacol; 1998 Jul; 9(4):319-28. PubMed ID: 10065920
[TBL] [Abstract][Full Text] [Related]
12. Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences.
Picker MJ; Yarbrough J; Hughes CE; Smith MA; Morgan D; Dykstra LA
J Pharmacol Exp Ther; 1993 Aug; 266(2):756-67. PubMed ID: 8394915
[TBL] [Abstract][Full Text] [Related]
13. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Zimmerman DM; Leander JD; Reel JK; Hynes MD
J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
[TBL] [Abstract][Full Text] [Related]
14. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
15. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
16. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
17. Opiate agonist-antagonist interactions: application of a three-key drug discrimination procedure.
France CP; Woods JH
J Pharmacol Exp Ther; 1985 Jul; 234(1):81-9. PubMed ID: 4009506
[TBL] [Abstract][Full Text] [Related]
18. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
19. beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
Spivak CE; Beglan CL; Zöllner C; Surratt CK
Synapse; 2003 Jul; 49(1):55-60. PubMed ID: 12710015
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
Takemori AE; Portoghese PS
J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]